METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression
© 2024. The Author(s)..
Without intervention, a considerable proportion of patients with metabolism-associated fatty liver disease (MAFLD) will progress from simple steatosis to metabolism-associated steatohepatitis (MASH), liver fibrosis, and even hepatocellular carcinoma. However, the molecular mechanisms that control progressive MAFLD have yet to be fully determined. Here, we unraveled that the expression of the N6-methyladenosine (m6A) methyltransferase METTL14 is remarkably downregulated in the livers of both patients and several murine models of MAFLD, whereas hepatocyte-specific depletion of this methyltransferase aggravated lipid accumulation, liver injury, and fibrosis. Conversely, hepatic Mettl14 overexpression alleviated the above pathophysiological changes in mice fed on a high-fat diet (HFD). Notably, in vivo and in vitro mechanistic studies indicated that METTL14 downregulation decreased the level of GLS2 by affecting the translation efficiency mediated by YTHDF1 in an m6A-depedent manner, which might help to form an oxidative stress microenvironment and accordingly recruit Cx3cr1+Ccr2+ monocyte-derived macrophages (Mo-macs). In detail, Cx3cr1+Ccr2+ Mo-macs can be categorized into M1-like macrophages and S100A4-positive macrophages and then further activate hepatic stellate cells (HSCs) to promote liver fibrosis. Further experiments revealed that CX3CR1 can activate the transcription of S100A4 via CX3CR1/MyD88/NF-κB signaling pathway in Cx3cr1+Ccr2+ Mo-macs. Restoration of METTL14 or GLS2, or interfering with this signal transduction pathway such as inhibiting MyD88 could ameliorate liver injuries and fibrosis. Taken together, these findings indicate potential therapies for the treatment of MAFLD progression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Signal transduction and targeted therapy - 9(2024), 1 vom: 17. Apr., Seite 91 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Yue-Fan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.04.2024 Date Revised 25.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41392-024-01797-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371164982 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371164982 | ||
| 003 | DE-627 | ||
| 005 | 20240425234906.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240417s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41392-024-01797-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM371164982 | ||
| 035 | |a (NLM)38627387 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Yue-Fan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Without intervention, a considerable proportion of patients with metabolism-associated fatty liver disease (MAFLD) will progress from simple steatosis to metabolism-associated steatohepatitis (MASH), liver fibrosis, and even hepatocellular carcinoma. However, the molecular mechanisms that control progressive MAFLD have yet to be fully determined. Here, we unraveled that the expression of the N6-methyladenosine (m6A) methyltransferase METTL14 is remarkably downregulated in the livers of both patients and several murine models of MAFLD, whereas hepatocyte-specific depletion of this methyltransferase aggravated lipid accumulation, liver injury, and fibrosis. Conversely, hepatic Mettl14 overexpression alleviated the above pathophysiological changes in mice fed on a high-fat diet (HFD). Notably, in vivo and in vitro mechanistic studies indicated that METTL14 downregulation decreased the level of GLS2 by affecting the translation efficiency mediated by YTHDF1 in an m6A-depedent manner, which might help to form an oxidative stress microenvironment and accordingly recruit Cx3cr1+Ccr2+ monocyte-derived macrophages (Mo-macs). In detail, Cx3cr1+Ccr2+ Mo-macs can be categorized into M1-like macrophages and S100A4-positive macrophages and then further activate hepatic stellate cells (HSCs) to promote liver fibrosis. Further experiments revealed that CX3CR1 can activate the transcription of S100A4 via CX3CR1/MyD88/NF-κB signaling pathway in Cx3cr1+Ccr2+ Mo-macs. Restoration of METTL14 or GLS2, or interfering with this signal transduction pathway such as inhibiting MyD88 could ameliorate liver injuries and fibrosis. Taken together, these findings indicate potential therapies for the treatment of MAFLD progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Methyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.1.1.- |2 NLM | |
| 650 | 7 | |a METTL14 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.1.1.- |2 NLM | |
| 650 | 7 | |a Myeloid Differentiation Factor 88 |2 NLM | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a Receptors, Chemokine |2 NLM | |
| 650 | 7 | |a S100 Calcium-Binding Protein A4 |2 NLM | |
| 650 | 7 | |a Mettl14 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 2.1.1.- |2 NLM | |
| 650 | 7 | |a S100a4 protein, mouse |2 NLM | |
| 650 | 7 | |a Myd88 protein, mouse |2 NLM | |
| 700 | 1 | |a Zhang, Wen-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhi-Xuan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Hao-Zan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zhi-Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Piao, Xian-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Ruan, Min-Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Zhi-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Si-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Mu, Chen-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Ji-Hang |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Shu-Han |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Fu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Signal transduction and targeted therapy |d 2016 |g 9(2024), 1 vom: 17. Apr., Seite 91 |w (DE-627)NLM257871861 |x 2059-3635 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:1 |g day:17 |g month:04 |g pages:91 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41392-024-01797-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 1 |b 17 |c 04 |h 91 | ||